ReShape Lifesciences Files S-1/A Update

TL;DR

ReShape Lifesciences filed an S-1/A update on Feb 7, 2025. Watch for potential stock moves.

AI Summary

ReShape Lifesciences Inc. filed an S-1/A on February 7, 2025, to update its registration statement. The company, formerly Obalon Therapeutics Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 1001 Calle Amanecer, San Clemente, CA.

Why It Matters

This filing indicates ongoing regulatory activity and potential future stock offerings or changes for ReShape Lifesciences, impacting investors and the market.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can introduce volatility.

Key Numbers

• 2834 — SIC Code (Indicates industry classification as Pharmaceutical Preparations.)
• 1231 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st.)

Key Players & Entities

• ReShape Lifesciences Inc. (company) — Filer of the S-1/A
• Obalon Therapeutics Inc. (company) — Former name of ReShape Lifesciences Inc.
• 20250207 (date) — Filing date of the S-1/A
• 333-283952 (dollar_amount) — SEC File Number
• 1001 Calle Amanecer, San Clemente, CA (location) — Business and mailing address

FAQ

Key Financial Figures

• $833.333 — ote in the original principal amount of $833.333.34 that we issued to Ascent on October
• $5.22 — 2024 at an initial conversion price of $5.22 per share (the "Convertible Note") and
• $5,000,000 — we may receive gross proceeds of up to $5,000,000 from the sale of common stock to Ascent
• $1.15 million — development has received approximately $1.15 million dollars of nondilutive NIH grant suppor
• $5.16 million — ur liabilities, for a purchase price of $5.16 million in cash, subject to adjustment based on

Filing Documents

• rsls-20240930xs1a.htm (S-1/A) — 6509KB
• rsls-20240930xs1a007.jpg (GRAPHIC) — 8KB
• rsls-20240930xs1a008.jpg (GRAPHIC) — 67KB
• 0001104659-25-010613.txt ( ) — 19350KB
• rsls-20240930.xsd (EX-101.SCH) — 80KB
• rsls-20240930_cal.xml (EX-101.CAL) — 115KB
• rsls-20240930_def.xml (EX-101.DEF) — 499KB
• rsls-20240930_lab.xml (EX-101.LAB) — 557KB
• rsls-20240930_pre.xml (EX-101.PRE) — 779KB
• rsls-20240930xs1a_htm.xml (XML) — 2482KB

RISK FACTORS

RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 47 CAPITALIZATION 48

USE OF PROCEEDS

USE OF PROCEEDS 49 MARKET AND DIVIDEND INFORMATION FOR OUR COMMON STOCK 50

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 51

BUSINESS

BUSINESS 64 EXECUTIVE AND DIRECTOR COMPENSATION 85 MANAGEMENT 88

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 95 DESCRIPTION OF EQUITY FINANCING TRANSACTION 96 DESCRIPTION OF CONVERTIBLE NOTE TRANSACTION 98 THE SELLING STOCKHOLDER 99

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 100 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 104 PLAN OF DISTRIBUTION 105 RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 107 LEGAL MATTERS 119 EXPERTS 119 WHERE YOU CAN FIND MORE INFORMATION 119 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 119 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 under which the selling stockholder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by the selling stockholder of the securities offered by them described in this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or our securities registered under the registration statement of which this prospectus forms a part are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions " Where You Can Find Additional Information " in this prospectus. Neither we nor the selling stockholder have authorized anyone to provide any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the

View Full Filing

View this S-1/A filing on SEC EDGAR